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Letter
Regarding the publication The Multiple Sclerosis
Severity Score: Fluctuations and prognostic ability
in a longitudinal cohort of patients with MS
authored by RH Gross et al
Richard Roxburgh , Ernest Willoughby and Shaun Seaman
Dear Editors
Regarding the publication The Multiple Sclerosis
Severity Score: Fluctuations and prognostic ability
in a longitudinal cohort of patients with MS, auth-
ored by RH Gross et al.1
We agree with the authors that the Multiple Sclerosis
Severity Score (MSSS) was devised as a descriptor
of disease severity for groups of patients and was
intended to be used for statistical comparisons
between such groups, and thence also to be useful
for stratification in clinical trials or just as a popu-
lation disease severity descriptor.2 Other researchers
have made claims for it as a prognostic measure for
individuals.3,4
Gross’s paper states that the MSSS methodology
assumes that a patient’s MSSS decile will ‘remain
. . . stable’. While we did show correlations between
the rankings of patients’ disability at one time point
and their rankings 15 years later, we made no such
assumptions of its stability. Gross et al. then present
data on a cohort of 122 patients with up to 25 years
of follow-up, highlighting the instability of MSSS
scores in these patients. We submit that there are
methodological and statistical factors which have
led to them overestimating this instability.
The most important methodological reason for fluc-
tuation in individual MSSS in Gross’s paper is that it
appears that the authors included Expanded
Disability Status Scale (EDSS) assessments at
times of relapse. The ‘baseline’ MSSS was largely
made at the ‘initial visit’ when the patient presented
with symptoms, and it is likely therefore that they
were in a relapse at that time. This would explain
why more patients (32.8%) had ‘better than
expected’ than ‘worse than expected’ (23.0%) out-
comes, and why, of the 72% who deviated from
their baseline MSSS, approximately 26% (reading
from their Kaplan–Meier curve, Figure 3) deviated
at or about their year 1 assessment. Also, recovery
from relapses is evident from the leftward-pointing
arrows (improving EDSS) in their Figure 2.
Similarly, in Gross’s paper, it is likely that some
of the variation, where an individuals’ MSSS was
found to be higher at later assessments than expected
from baseline, was due to them being assessed at
times of later relapse. As explicitly stated in our
paper, we made every effort to avoid incorporating
EDSSs made at time of relapse.
Secondly there is the issue of the small proportion of
patients that are followed up over the years which,
especially as the cohort was fairly small to begin
with, led to unsurprisingly wild fluctuations in
mean MSSS. In spite of this the authors have
chosen to highlight, for example, that (compared
with the baseline mean MSSS of 3.93) the highest
mean MSSS was 5.65 at 19 years’ follow-up, which
was based on the data from a handful of patients at
most (Figure 4 shows only 14 patients followed up at
16 years). Similarly, examining the whole of the right
side of the Kaplan–Meier plot (their Figure 3), shows
that it is based on five or fewer patients.
We maintain therefore that the MSSS is more reli-
able than is portrayed in this paper. However,
we would continue to support the use of the MSSS
primarily as a tool for characterising groups of
patients.
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